Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
admission, ago, Albania, amyloid, Arab, Argentina, Argentine, Asian, ASU, axitinib, bond, capability, cardiomyopathy, category, center, CentreOne, Chemistry, Chile, choose, Citrate, classification, classified, contemplated, content, coordinated, critical, cumulative, curve, customer, dedicated, DICOM, diligently, DIPRO, disaggregate, disagreement, distributor, duration, earlier, evenly, exacerbation, feedback, filgrastim, flexibility, formation, forum, fulvestrant, genuine, GPD, grown, Guaranty, headcount, highlight, imbalance, implied, issuer, junction, Kuwait, lawsuit, lessee, lessor, Macau, matrix, melanoma, methotrexate, midpoint, migrate, minimum, mutual, Nivestim, Northern, NovaQuest, orderly, organizational, ovarian, physical, point, prepayment, proprietary, quickly, rapidly, readily, recovery, redeploy, rescinded, rivipansel, RPI, Scandinavia, smoking, software, spot, stake, steady, summarized, tablet, thromboembolism, transthyretin, twelve, undertaken, unified, Unregistered, unresolved, upholding, urothelial, variable, VAT, zeta
Removed:
acceptance, affiliated, Alabama, announcement, antigen, antirheumatic, Apotex, applied, approvable, Aricept, arterial, Aurobindo, Australian, bazedoxifene, began, bolivar, bulk, CDK, celecoxib, cellular, certiorari, CFT, characterizing, Chimeric, claimed, claiming, combining, concept, conjugated, convene, conversion, converted, CR, damaged, decided, deferral, define, devaluation, devalued, diabetic, directed, disclose, dolutegravir, doubt, Duavee, Dyskinesia, embedded, ER, estrogen, exhausted, expectancy, exploring, failing, feature, forward, freeze, gain, gastroesophageal, gave, GlaxoSmithKline, Governor, GSK, half, Hetero, HIV, host, immunodeficiency, importance, improving, infection, InnoPharma, innovator, instrument, intensified, invalidating, liable, medicine, metric, Mexican, modified, Neurontin, nicotine, nonclinical, Office, ownership, parent, partner, path, petition, pivotal, planning, postmenopausal, predecessor, preferential, prescribing, priority, produced, promote, proof, prospectively, Rapamune, reconsideration, recover, reflux, Reglan, reissue, rejected, remeasured, remeasuring, renewal, retrospective, Revatio, reversible, reversing, rheumatologist, seizure, select, selective, skin, solution, Spiriva, split, steadily, stipulated, suing, Supreme, surface, sympathetic, Tardive, theory, thereto, timeframe, Tivicay, tobacco, traditional, transitional, treating, Trumenba, ulcerative, unspecified, ViiV, Viviant, wage, waiting, waiver, Watson
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Pfizer Supplemental Savings Plan
- 12 Computation of Ratio of Earnings to Fixed Charges
- 15 Accountants' Acknowledgement
- 31.1 Certification by the CEO - Section 302
- 31.2 Certification by the CFO - Section 302
- 32.1 Certification by the CEO - Section 1350
- 32.2 Certification by the CFO - Section 1350
- Download Excel data file
- View Excel data file
Related press release
PFE similar filings
Filing view
External links